EUCTR2005-000454-73-GB进行中（未招募）1 期
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, 3-ARM STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF LENALIDOMIDE VERSUS PLACEBO IN RED BLOOD CELL (RBC) TRANSFUSION-DEPENDENT SUBJECTS WITH LOW- OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES (MDS) ASSOCIATED WITH A DELETION (DEL) 5Q[31] CYTOGENETIC ABNORMALITY
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 205
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Pre-randomization Phase:
- •1. Must understand and voluntarily sign an informed consent form.
- •2. Must be =18 years of age at the time of signing the informed consent form
- •3. Must be able to adhere to the study visit schedule and other protocol requirements.
- •4. Concurrent corticosteroids used for medical conditions other than MDS is allowed provided subject is on a stable or decreasing dose for =1week prior to study entry
- •5. Prior thalidomide allowed
- •6. Documented diagnosis of MDS that meets IPSS criteria for low- to intermediate-1-risk disease and has an associated del 5q[31] cytogenetic abnormality (the deleted chromosomal region must include 5q[31]
- •7. RBC transfusion-dependent anemia defined as not having any consecutive 56 days without a RBC transfusion within at least the immediate 112 days (4 months). Note: A 112 day documented transfusion history is required for subjects to enter the double-blind phase of the study.
- •Double-blind randomization Phase:
- •As point 1-3, 6 and 7 above, plus:
- •1. Baseline RBC transfusion requirement has been calculated
- •2. Female subjects of childbearing potential must:
- •- Understand that the study medication could have a potential teratogenic risk
- •- Agree to use, and be able to comply with, effective contraception without
- •interruption, 28 days before starting study drug, throughout study drug therapy
- •(including dose interruptions) and for 28 days after the end of study drug therapy,
- •even if she has amenorrhoea. This applies unless the subject commits to absolute and continued abstinence confirmed on a monthly basis. The following are effective
- •methods of contraception: implant, Levonorgestrel-releasing intrauterine system, Medroxyprogesterone acetate depot, Tubal sterilisation, Sexual intercourse with a vasectomised male partner only; vasectomy must be confirmed by two negative semen analyses, Ovulation inhibitory progesterone-only pills (i.e., desogestrel).
- •- Agree to have a medically supervised pregnancy test with a minimum sensitivity of
- •25 IU/ml not more than 3 days from the start of study medication once the subject has been on effective contraception for at least 28 days. This requirement also applies to females of childbearing potential who practice complete and continued abstinence.
- •- Agree to have a medically supervised pregnancy test every 28 days including 28 days after the end of study treatment, except in the case of confirmed tubal sterilization. These tests should be performed not more than 3 days before the start of next treatment. This requirement also applies to females of childbearing potential who practice complete and continued abstinence.
- •8. Male subjects must:
- •- Agree to use condoms throughout study drug therapy, during any dose interruption and for 7 days after cessation of study therapy if their partner is of childbearing potential and has no contraception.
- •- Agree not to donate semen during study drug therapy and for 7 days after end of
- •study drug therapy.
- •9. All subjects must:
- •- Agree to abstain from donating blood w
排除标准
- •Pre-randomization phase:
- •1. Pregnant or lactating females.
- •2. Prior therapy with lenalidomide
- •3. Proliferative (WBC=12,000/mL) chronic myelomonocytic leukemia (CMML)
- •4. Prior =grade-2 NCI CTCAE allergic reaction to thalidomide
- •5. Prior desquamating (blistering) rash while taking thalidomide
- •6. Prior history of malignancy other than MDS (except basal cell or squamous cell carcinoma or carcinoma in situ of the cervix or breast) unless the subject has been free of disease for =3years
- •7. Use of cytotoxic chemotherapeutic agents or experimental agents (agents that are not commercially available) for the treatment of MDS within 28 days of Day 1 of the Pre-Randomization Phase.
- •8. Less than 6 months since prior allogeneic bone marrow transplantation of Day 1 of the Pre-Randomization Phase.
- •9. Less than 3 months since prior autologous bone marrow or stem cell transplantation of Day 1 of the Pre-Randomization Phase.
- •10. Less than 28 days since prior myelosuppressive anticancer biologic therapy of Day 1 of the Pre-Randomization Phase.
- •11. Use of erythropoiesis stimulating growth factors (e.g. recombinant human erythropoietin (rHuEPO) within 28 days or long-acting erythropoiesis stimulating growth factor (e.g. darbepoetin) with 56 days of Day 1 of the Pre-Randomization Phase
- •12. Use of androgens other than to treat hypogonadism is prohibited.
- •13. Known HIV-1 positivity
- •14. Any serious medical condition or psychiatric illness that will prevent the subject from signing the informed consent form or will place the subject at unacceptable risk if he or she participates in the study
- •Double-blind randomization Phase:
- •As points 1-6, 12, 13 and 14 above, plus:
- •1. Any of the following laboratory abnormalities:
- •- Absolute neutrophil count (ANC) < 500 cells/ µL (0.5 x 10^9/L)
- •- Platelet count < 25,000/µL (25 x 10^9/L)
- •- Serum creatinine > 2.0 mg/dL (177 mmol/L)
- •- Serum aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase
- •(SGOT) or alanine transaminase (ALT)/serum glutamate pyruvate transaminase
- •(SGPT) > 3.0 x upper limit of normal (ULN) unless it is clinically due to iron
- •overload from blood transfusions.
- •- Serum total bilirubin > 1.5 mg/dL
- •2. Clinically significant anemia owing to iron, B12, or folate deficiencies, or autoimmune or hereditary hemolysis or gastrointestinal bleeding (the subject must have a marrow aspirate that is evaluable for storage iron)
研究者
相似试验
进行中（未招募）
不适用
A study to evaluate if Lenalidomide works in patients with myelodysplastic syndrome and with a special genetic characteristic of the disease, and who need to receive blood transfusioTransfusion-dependant, low-or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormalityEUCTR2005-000454-73-DECelgene Corporation135
进行中（未招募）
不适用
A study to evaluate if Lenalidomide works in patients with myelodysplastic syndrome and with a special genetic characteristic of the disease, and who need to receive blood transfusioTransfusion-dependant, low-or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormalityEUCTR2005-000454-73-BECelgene Corporation205
进行中（未招募）
不适用
A study to evaluate if Lenalidomide works in patients with myelodysplastic syndrome and with a special genetic characteristic of the disease, and who need to receive blood transfusioTransfusion-dependant, low-or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormalityEUCTR2005-000454-73-SECelgene Corporation205
招募中
不适用
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TOEVALUATE THE EFFICACY AND SAFETY OFDAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITHMODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUSERYTHEMATOSUS-M32 Systemic lupus erythematosusM32Systemic lupus erythematosusPER-046-20CB Biopharma SRL,
进行中（未招募）
1 期
A Study of RO6885247 in Adult and Pediatric Patients with Spinal Muscular Atrophy (MOONFISH)MedDRA version: 18.0Level: PTClassification code 10041582Term: Spinal muscular atrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersSpinal Muscular AtrophyEUCTR2014-002246-41-ESRoche Farma S.A., en nombre de F. Hoffmann-La Roche Ltd.64